Samjo Management LLC Acquires 1,034,312 Shares of MDxHealth SA (NASDAQ:MDXH)

Samjo Management LLC boosted its position in MDxHealth SA (NASDAQ:MDXH - Free Report) by 130.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,824,312 shares of the company's stock after purchasing an additional 1,034,312 shares during the quarter. MDxHealth comprises about 1.6% of Samjo Management LLC's portfolio, making the stock its 19th biggest holding. Samjo Management LLC owned approximately 3.86% of MDxHealth worth $4,324,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Maven Securities LTD bought a new position in MDxHealth in the 3rd quarter valued at about $208,000. Oppenheimer & Co. Inc. lifted its stake in MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock worth $47,000 after purchasing an additional 10,000 shares during the last quarter. Perkins Capital Management Inc. boosted its holdings in shares of MDxHealth by 31.6% in the 4th quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock valued at $2,331,000 after purchasing an additional 236,100 shares in the last quarter. Finally, Geode Capital Management LLC bought a new position in shares of MDxHealth in the 4th quarter valued at $25,000.

MDxHealth Price Performance

NASDAQ:MDXH traded down $0.01 during trading hours on Thursday, hitting $1.41. The company's stock had a trading volume of 30,690 shares, compared to its average volume of 82,811. MDxHealth SA has a twelve month low of $1.35 and a twelve month high of $3.50. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The stock has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $1.92. The company has a market capitalization of $66.44 million, a P/E ratio of -0.92 and a beta of 1.29.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. On average, analysts anticipate that MDxHealth SA will post -1.15 EPS for the current fiscal year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.